Biochemical Engineering Special Interest Group
biological engineering professionals
14 July 2016

Avacta and Glythera partner to develop alternative ADC

Avacta Group PLC said on Thursday it would collaborate with Glythera Ltd to develop a new, highly targeted bio-therapeutics as an alternative to established antibody drug conjugates. The company said the combined potential benefits of the collaboration could create a new leading antibody drug conjugate, with a number of benefits over current products. Avacta said their Affimer-drug technology could improve tumour penetration, while Glythera's PermaLink technology could reduce toxicity effects. Source: London & SE News 14/7/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).